Evogene (EVGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evogene (EVGN) has a cash flow conversion efficiency ratio of -0.220x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-3.79 Million ≈ $-10.16K USD) by net assets (ILA17.25 Million ≈ $46.25K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Evogene for the company's overall valuation and market capitalisation.
Evogene - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how Evogene's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Evogene Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evogene ranked by their cash flow conversion efficiency. Explore EVGN cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Audeara Ltd
AU:AUA
|
0.024x |
|
Hargreaves Services Plc
LSE:HSP
|
0.133x |
|
Conifex Timber Inc
TO:CFF
|
0.005x |
|
PROSPECT RIDGE RESOURCES
F:0ED
|
-0.292x |
|
Pool Safe Inc
V:POOL
|
-3.557x |
|
BioNexus Gene Lab Corp Common stock
NASDAQ:BGLC
|
-0.181x |
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
-0.119x |
|
Bioter S.A.
AT:BIOT
|
0.009x |
Annual Cash Flow Conversion Efficiency for Evogene (2008–2024)
The table below shows the annual cash flow conversion efficiency of Evogene from 2008 to 2024. View Evogene (EVGN) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA14.84 Million ≈ $39.78K |
ILA-19.70 Million ≈ $-52.82K |
-1.328x | -76.50% |
| 2023-12-31 | ILA28.68 Million ≈ $76.90K |
ILA-21.58 Million ≈ $-57.85K |
-0.752x | -10.52% |
| 2022-12-31 | ILA34.79 Million ≈ $93.27K |
ILA-23.68 Million ≈ $-63.48K |
-0.681x | -73.77% |
| 2021-12-31 | ILA63.42 Million ≈ $170.03K |
ILA-24.84 Million ≈ $-66.59K |
-0.392x | -14.17% |
| 2020-12-31 | ILA56.88 Million ≈ $152.50K |
ILA-19.51 Million ≈ $-52.32K |
-0.343x | -18.97% |
| 2019-12-31 | ILA60.22 Million ≈ $161.44K |
ILA-17.36 Million ≈ $-46.55K |
-0.288x | +4.32% |
| 2018-12-31 | ILA50.31 Million ≈ $134.87K |
ILA-15.16 Million ≈ $-40.65K |
-0.301x | -31.26% |
| 2017-12-31 | ILA69.38 Million ≈ $186.00K |
ILA-15.93 Million ≈ $-42.71K |
-0.230x | -71.40% |
| 2016-12-31 | ILA87.29 Million ≈ $234.02K |
ILA-11.69 Million ≈ $-31.35K |
-0.134x | -12.02% |
| 2015-12-31 | ILA103.75 Million ≈ $278.16K |
ILA-12.41 Million ≈ $-33.26K |
-0.120x | -56.06% |
| 2014-12-31 | ILA116.08 Million ≈ $311.21K |
ILA-8.89 Million ≈ $-23.85K |
-0.077x | -81.38% |
| 2013-12-31 | ILA124.75 Million ≈ $334.44K |
ILA-5.27 Million ≈ $-14.13K |
-0.042x | -7.98% |
| 2012-12-31 | ILA48.26 Million ≈ $129.38K |
ILA-1.89 Million ≈ $-5.06K |
-0.039x | -188.20% |
| 2011-12-31 | ILA48.09 Million ≈ $128.92K |
ILA2.13 Million ≈ $5.72K |
0.044x | -3.18% |
| 2009-12-31 | ILA19.34 Million ≈ $51.85K |
ILA886.00K ≈ $2.38K |
0.046x | -96.51% |
| 2008-12-31 | ILA9.61 Million ≈ $25.76K |
ILA12.61 Million ≈ $33.80K |
1.312x | -- |
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through… Read more